Interview with Fabio Rosa, Co-Founder and Head of Research of Asgard Therapeutics

The EIC Scaling Club Podcast on European Deep Tech
29/01/2025 12 min Episodio 28
Interview with Fabio Rosa, Co-Founder and Head of Research of Asgard Therapeutics

Listen "Interview with Fabio Rosa, Co-Founder and Head of Research of Asgard Therapeutics"

Descargar episodio Ver en sitio original

Episode Synopsis


In this interview, Fabio Rosa, Co-Founder and Head of Research at Asgard Therapeutics, discusses their groundbreaking cancer therapy, AT108, which reprograms cancer cells into immune cells. Asgard has raised €30 million in Series A funding and is preparing for clinical trials by 2027. With strong scientific validation and key publications, the company is now focused on partnerships, production scaling, and investor relations to drive its innovative therapy forward.

More episodes of the podcast The EIC Scaling Club Podcast on European Deep Tech

Transforming Patient Monitoring | Kaja from Checkpoint Care at the EIC Scaling Club 28/10/2025
Powering the Hydrogen Future | Guillermo from H2SITE at the EIC Scaling Club Ambition Forum 28/10/2025
Innovating in Women’s Health | Marina from Mimark Diagnostics at the EIC Scaling Club Ambition Forum 17/10/2025
Scaling Green Hydrogen | Sune from Dynelectro at the EIC Scaling Club Ambition Forum 2025 17/10/2025
Interview with Torbjørn Blom Hagen, CFO of N2 Applied 12/05/2025
Interview with Nick Kanopoulos, CEO of Brite Hellas S.A. 12/05/2025
Interview with Bostjan Bozic, COO of Trapview Unlisted 12/05/2025
Interview with Aina Hegrestad, CFO of Nordic Electrofuel AS 12/05/2025
Interview with Nis Benn, Founder and Chief Commercial Officer of Hyme Energy 02/05/2025
Interview with David Pistoni, CEO and Co-Founder of Zeleros 29/04/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA